In medicine, there is a specific point at which a medication ceases to be effective for its intended purpose. GLP-1 receptor agonists are currently experiencing that moment, and it is truly strange, in the best way possible, to watch it play out.
These medications, which include liraglutide, tirzepatide, semaglutide, and an increasing number of others, were initially authorized to control blood sugar levels in individuals with type 2 diabetes. That was the initial brief. a comparatively small mandate. However, over the past few years, data began to accumulate in unexpected ways, and now transplant specialists, cardiologists, and oncologists are all closely monitoring a class of drugs that were previously thought to be firmly within the purview of endocrinologists.
The hormone the body naturally produces after eating is called GLP-1, or glucagon-like peptide-1. By imitating that hormone, the receptor agonists slow digestion, decrease appetite, and instruct the pancreas to release insulin. On paper, it seems fairly straightforward. However, the receptor that these medications target is found not only in the pancreas but also in the brain, the cardiovascular system, immune cells, and the bone marrow itself, as researchers are now more precisely documenting.
A peer-reviewed narrative review that looked at the connection between GLP-1-based treatments and blood cancers was published in Cureus in August 2026. A few years ago, this would have seemed improbable. The authors took care to note that the results did not establish causation.
However, a noteworthy pattern emerged from extensive observational studies. GLP-1 receptor agonist use was linked to a 54% lower risk of developing hematological malignancies overall, including significant reductions in myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma, when compared to insulin therapy, according to one propensity score-matched cohort study. GLP-1 receptor agonists still performed better on myelodysplastic syndromes and myeloproliferative neoplasms than metformin, which already has a modest reputation for possible cancer-protective effects.
Whether these are direct drug effects or result from the effects of GLP-1 receptor agonists on inflammation and obesity is still unknown. Type 2 diabetes and obesity are both independently linked to an increased risk of blood cancer. Both are addressed by the medications. The suppression of NF-κB inflammatory signaling, changes in macrophage behavior from pro-tumor to anti-tumor, and enhancements in the way immune cells monitor and react to aberrant growth are some of the early mechanistic signals that indicate something more specific is taking place. Combining a GLP-1 receptor agonist with an anti-inflammatory antibody actually decreased the burden of leukemic disease, according to a mouse model study. There is no clinical recommendation for that. However, it’s the kind of discovery that funds research initiatives.
In contrast, the cardiovascular evidence has advanced far beyond preliminary. In comparison to sitagliptin, a common diabetes medication with no discernible impact on heart outcomes, tirzepatide was linked to a 32% relative decrease in major adverse cardiovascular events, according to a study published in The BMJ in August 2026 that examined real-world data from over 52,000 patients. One cardiovascular event was avoided for every 70 patients who began tirzepatide. For every 122 patients, one death was avoided. In a population that is already at significant risk, those figures are significant.
This doesn’t exist in a vacuum. GLP-1 receptor agonists have incredible commercial momentum. Between 2019 and 2024, prescriptions in the US increased by 587%. In the last two years, deal activity in the obesity and metabolic disease space has almost doubled. Examples of how seriously the industry is betting on this space include Pfizer’s $10 billion acquisition of Metsera and Roche’s $5.3 billion deal for Zealand Pharma’s petrelintide. There are new oral formulations being developed. Trials for ultra-long-acting versions, which are administered monthly or possibly even once a year, are underway. Businesses are attempting to solve the one issue that plagues long-term use: the loss of both fat and lean muscle mass.
It seems like the medical community is still learning about the potential of these medications. For a class of treatments that swiftly transitioned from niche approval to broad adoption, that is not out of the ordinary. Science often lags behind prescribing. However, the picture that is emerging in the fields of cardiology, metabolic medicine, and now hematology is one of a class of drugs that no one could have predicted when the first GLP-1 receptor agonist was approved decades ago.
We’re still figuring out what that ultimately means for patients, especially those who are managing several conditions at once. Despite being striking, the evidence regarding blood cancer risk is still observational. In many areas, long-term follow-up data are still scarce. Additionally, access is still a significant and unsolved issue; a population that cannot afford the treatment cannot benefit from the cardiovascular benefits.
However, it’s difficult to ignore how the discourse surrounding GLP-1 receptor agonists has changed. What started out as a medication for diabetes is now discussed in relation to immune modulation, heart survival, and cancer prevention. One receptor has a lot of ground to cover.
